Want to see IN:UNICHEMLAB full AI Analyst Report?
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹685.95
Previous CloseN/A
Volume14.19K
Average Volume (3M)1.03K
Market Cap
₹37.93B
Enterprise Value₹22.74K
Total Cash (Recent Filing)₹2.99B
Total Debt (Recent Filing)₹5.00B
Price to Earnings (P/E)12.5
Beta1.31
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)35.91
Shares Outstanding70,405,754
10 Day Avg. Volume1,013
30 Day Avg. Volume1,033
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.76
Price to Sales (P/S)0.94
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / Strong Balance SheetLow debt ratios and growing equity provide durable financial flexibility. A conservative balance sheet supports funding for regulatory approvals, manufacturing scale-ups or cyclical downturns without immediate refinancing pressure, reducing solvency and liquidity risk over the medium term.
Diversified Business Mix And Manufacturing CapabilityExposure across domestic branded formulations, international finished doses and API manufacturing creates multiple revenue pillars. Strong manufacturing and regulatory compliance underpin supply continuity and market access, lowering concentration risk and supporting steady long-term cash generation potential.
Return To Profitability With Improved Net MarginTransition back to net profitability and a higher net margin reflects improving cost control or pricing in key segments. Sustaining this improvement can rebuild retained earnings, enable reinvestment, and reduce reliance on external funding, strengthening medium-term financial resilience.
Bears Say
Weak Cash Generation / Negative OCF And FCFConsistent negative operating and free cash flow indicates poor cash conversion of earnings and/or heavy reinvestment. This undermines the firm's ability to self-fund capex, pay down liabilities, or return capital, increasing dependence on external financing and execution risk over time.
Thin And Volatile Operating ProfitabilityLow operating margins offer a small buffer against raw material, pricing, or reimbursement shocks. Coupled with volatile gross margins, this reduces predictability of core earnings and limits the company's ability to absorb adverse industry cycles without cutting investment or margins further.
Recent Revenue Contraction And Uneven GrowthA reversal to negative top-line growth signals competitive pressures, loss of share, or product issues. Reduced revenue momentum can erode scale benefits and pressure margins and cash flow, making it harder to invest in registrations, R&D or commercial expansion over the medium term.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹685.95 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹37.93B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is Nov 04, 2026 which is in 80 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on Aug 11, 2026. The company reported ₹5.89 earnings per share for the quarter, beating the consensus estimate of N/A by ₹5.89.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹5.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 13.062%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Windlas Biotech Ltd.
―